RU2377253C2 - Антитела, специфичные к фактору некроза опухолей, и их применение - Google Patents
Антитела, специфичные к фактору некроза опухолей, и их применение Download PDFInfo
- Publication number
- RU2377253C2 RU2377253C2 RU2005116225/13A RU2005116225A RU2377253C2 RU 2377253 C2 RU2377253 C2 RU 2377253C2 RU 2005116225/13 A RU2005116225/13 A RU 2005116225/13A RU 2005116225 A RU2005116225 A RU 2005116225A RU 2377253 C2 RU2377253 C2 RU 2377253C2
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- acid sequence
- monoclonal antibody
- human monoclonal
- light chain
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к иммунологии и биотехнологии. Предложено моноклональное антитело человека, специфичное в отношении ФНО-альфа (TNF-alpha), содержащее легкую и тяжелую цепь с соответствующими CDR3 участками. Описаны его варианты, в том числе на основе тяжелой и легкой цепи, которые кодируются генами человека VH3-33 и A30VK1 или VH3-53 и L2VK3, соответственно. Раскрыты: способ оценки содержания ФНО-альфа (TNF-alpha) в образце пациента с использованием указанных антител и использование антител для приготовления лекарственного препарата. Описаны: составы для диагностики и лечения состояний, связанных с активностью ФНО-альфа (TNF-alpha) на основе антител. Раскрыта кодирующая нуклеиновая кислота, клетка для получения антител и способ получения антител. Использование изобретения обеспечивает высокоаффинные нейтрализующие моноклональные антитела, обладающие улучшенными Kd и IC50, по сравнению с Infliximab, Adalimumab или Etanercept, что может найти применение в медицине для лечения и диагностики заболеваний, связанных с повышенной активностью ФНО-альфа (TNF-alpha). 11 н. и 24 з.п. ф-лы, 13 ил., 36 табл.
Description
Claims (35)
1. Моноклональное антитело человека, которое специфическим образом связывается с фактором некроза опухолей альфа (ФНО-альфа) и содержит:
вариабельную область тяжелой цепи, которая содержит гипервариабельный участок 3 (CDR3) тяжелой цепи, который имеет последовательность аминокислот Glu Val Glu Ser Ala Met Gly Gly Phe Tyr Tyr Asn Gly Met Asp Val, и
вариабельную область легкой цепи, содержащую гипервариабельный участок 3 (CDR3) легкой цепи, который имеет последовательность аминокислот Leu Gin His Lys Ser Tyr Pro Leu Thr.
вариабельную область тяжелой цепи, которая содержит гипервариабельный участок 3 (CDR3) тяжелой цепи, который имеет последовательность аминокислот Glu Val Glu Ser Ala Met Gly Gly Phe Tyr Tyr Asn Gly Met Asp Val, и
вариабельную область легкой цепи, содержащую гипервариабельный участок 3 (CDR3) легкой цепи, который имеет последовательность аминокислот Leu Gin His Lys Ser Tyr Pro Leu Thr.
2. Моноклональное антитело человека по п.1, содержащее гипервариабельный участок 2 (CDR2) тяжелой цепи, который имеет последовательность аминокислот Val Ile Trp Ser Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys Gly.
3. Моноклональное антитело человека по п.1 или 2, содержащее гипервариабельный участок 1 (CDR1) тяжелой цепи, который имеет последовательность аминокислот Ser Tyr Asp Met His.
4. Моноклональное антитело человека по п.1 или 2, последовательность аминокислот тяжелой цепи которого содержит последовательность аминокислот SEQ ID NO: 70.
5. Моноклональное антитело человека по п.1 или 2, последовательность аминокислот тяжелой цепи которого содержит последовательность аминокислот SEQ ID NO: 74.
6. Моноклональное антитело человека по п.1 или 2, содержащее гипервариабельный участок 1 (CDR1) легкой цепи, который имеет последовательность аминокислот Arg Ala Ser Gln Gly lle Arg Ile Asp Leu Gly.
7. Моноклональное антитело человека по п.1 или 2, содержащее гипервариабельный участок 2 (CDR2) легкой цепи, который имеет последовательность аминокислот Ala Ala Ser Thr Leu Gln Ser.
8. Моноклональное антитело человека по п.1 или 2, последовательность аминокислот легкой цепи которого содержит последовательность аминокислот SEQ ID NO: 72.
9. Моноклональное антитело человека, которое специфически связывает фактор некроза опухолей альфа и содержит:
тяжелую цепь, которая содержит последовательность аминокислот, кодируемую геном VH3-33 человека, или ее консервативный вариант, и
легкую цепь, содержащую последовательность аминокислот, кодируемую геном легкой цепи A30VK1 человека, или ее консервативный вариант.
тяжелую цепь, которая содержит последовательность аминокислот, кодируемую геном VH3-33 человека, или ее консервативный вариант, и
легкую цепь, содержащую последовательность аминокислот, кодируемую геном легкой цепи A30VK1 человека, или ее консервативный вариант.
10. Моноклональное антитело человека, которое специфическим образом связывается с фактором некроза опухолей альфа и содержит:
вариабельную область тяжелой цепи, которая содержит гипервариабельный участок 3 (CDR3) тяжелой цепи, который имеет последовательность аминокислот Gly Glu Gly Gly Phe Asp Tyr, и
вариабельную область легкой цепи, которая содержит гипервариабельный участок 3 (CDR3) легкой цепи, который имеет последовательность аминокислот Gln Gln Tyr Asn Tyr Trp Trp Thr.
вариабельную область тяжелой цепи, которая содержит гипервариабельный участок 3 (CDR3) тяжелой цепи, который имеет последовательность аминокислот Gly Glu Gly Gly Phe Asp Tyr, и
вариабельную область легкой цепи, которая содержит гипервариабельный участок 3 (CDR3) легкой цепи, который имеет последовательность аминокислот Gln Gln Tyr Asn Tyr Trp Trp Thr.
11. Моноклональное антитело человека по п.10, содержащее гипервариабельный участок 2 (CDR2) тяжелой цепи, который имеет последовательность аминокислот Val Ile Tyr Ser Gly Asp Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly.
12. Моноклональное антитело человека по п.10 или 11, содержащее гипервариабельный участок 1 (CDR1) тяжелой цепи, который имеет последовательность аминокислот Arg Asn Tyr Met Ser.
13. Моноклональное антитело человека по п.10 или 11, последовательность аминокислот тяжелой цепи которого содержит последовательность аминокислот SEQ ID NO: 50.
14. Моноклональное антитело человека по п.10 или 11, содержащее гипервариабельный участок 1 (CDR1) легкой цепи, который имеет последовательность аминокислот Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala.
15. Моноклональное антитело человека по п.10 или 11, содержащее гипервариабельный участок 2 (CDR2) легкой цепи, который имеет последовательность аминокислот Gly Ala Ser Ile Arg Ala Thr.
16. Моноклональное антитело человека по п.10 или 11, содержащее гипервариабельный участок 3 (CDR3) легкой цепи, который имеет последовательность аминокислот Gln Gln Tyr Asn Tyr Trp Trp Thr.
17. Моноклональное антитело человека по п.10 или 11, последовательность аминокислот легкой цепи которого содержит последовательность аминокислот SEQ ID NO: 52.
18. Моноклональное антитело человека, которое специфически связывает фактор некроза опухолей альфа и содержит:
тяжелую цепь, которая содержит последовательность аминокислот, кодируемую геном VH3-53 человека, или консервативный вариант указанной последовательности, и легкую цепь, которая содержит последовательность аминокислот, кодируемую геном легкой цепи L2VK3 человека, или консервативный вариант указанной последовательности.
тяжелую цепь, которая содержит последовательность аминокислот, кодируемую геном VH3-53 человека, или консервативный вариант указанной последовательности, и легкую цепь, которая содержит последовательность аминокислот, кодируемую геном легкой цепи L2VK3 человека, или консервативный вариант указанной последовательности.
19. Моноклональное антитело человека согласно любому из пп.1, 2, 9-11 и 18, которое связывает ФНОа с Kd менее 10-10 М.
20. Моноклональное антитело человека согласно п.19, которое связывает ФНОа с Kd менее 10-11 М.
21. Моноклональное антитело человека согласно любому из пп.1, 2, 9-11, 18, которое продуцировано линией гибридомы.
22. Моноклональное антитело человека согласно любому из пп.1, 2, 9-11, 18, которое продуцировано СНО клетками.
23. Моноклональное антитело человека согласно любому из пп.1, 2, 9-11, 18, которое представляет собой IgG1.
24. Моноклональное антитело человека согласно любому из пп.1, 2, 9-11, 18, которое представляет собой IgG2.
25. Способ оценки содержания фактора некроза опухолей альфа (ФНОα) в образце, взятом у пациента, согласно которому антитело против ФНОα согласно любому из пп.1-24 приводят в контакт с биологическим образцом, взятым у пациента, и определяют степень связывания указанного антитела с ФНОα в указанном образце, причем концентрацию ФНОα в указанном образце определяют на основании количества ФНОα, связанного с указанным антителом.
26. Способ по п.25, где биологический образец представляет собой кровь.
27. Состав для диагностики состояний, связанных с активностью и/или повышенной продукцией ФНОα, содержащий эффективное количество антитела по любому из пп.1-24 или его функциональный фрагмент и фармацевтически приемлемый носитель.
28. Применение антитела согласно любому из пп.1-24 для приготовления лекарственного препарата для эффективного лечения опухолевых заболеваний, иммунно-опосредованных воспалительных заболеваний или апоптоза, индуцированного фактором некроза опухолей у животного.
29. Применение по п.28, где указанное опухолевое заболевание выбирают из следующей группы: рак груди, рак яичников, рак желчного пузыря, рак легких, глиобластома, рак желудка, рак эндометрия, рак почек, рак толстой кишки, рак поджелудочной железы, рак простаты.
30. Применение по п.28, где указанное иммунно-опосредованное воспалительное заболевание выбирают из следующей группы: ревматоидный артрит, гламерулонефрит, атеросклероз, псориаз, рестеноз, аутоиммунная болезнь, болезнь Крона, отторжение трансплантата, септический шок, кахексия, анорексия, анкилозный спондилит, множественный склероз.
31. Применение по п.28, где указанное иммунно-опосредованное воспалительное заболевание выбирают из группы, включающей ревматоидный артрит, псориаз и болезнь Крона.
32. Нуклеиновая кислота, которая кодирует антитело согласно любому из пп.1-24.
33. Клетка-хозяин для продуцирования антител, охарактеризованных в любом из пп.1-24, которая содержит нуклеиновую кислоту по п.32.
34. Способ получения антитела, который включает
культивирование клетки по п.33 в условиях, при которых указанная нуклеиновая кислота экспрессируется с образованием антитела, и выделение антитела.
культивирование клетки по п.33 в условиях, при которых указанная нуклеиновая кислота экспрессируется с образованием антитела, и выделение антитела.
35. Состав для лечения состояний, связанных с активностью и/или повышенной продукцией ФНОα, содержащий эффективное количество антитела по любому из пп.1-24 или его функциональный фрагмент и фармацевтически приемлемый носитель.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43072902P | 2002-12-02 | 2002-12-02 | |
US60/430,729 | 2002-12-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005116225A RU2005116225A (ru) | 2006-02-27 |
RU2377253C2 true RU2377253C2 (ru) | 2009-12-27 |
Family
ID=32469516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005116225/13A RU2377253C2 (ru) | 2002-12-02 | 2003-12-02 | Антитела, специфичные к фактору некроза опухолей, и их применение |
Country Status (13)
Country | Link |
---|---|
US (2) | US7285269B2 (ru) |
EP (1) | EP1578799B8 (ru) |
JP (1) | JP4754219B2 (ru) |
CN (1) | CN100434440C (ru) |
AT (1) | ATE472556T1 (ru) |
AU (1) | AU2003298816C1 (ru) |
CA (1) | CA2508375C (ru) |
DE (1) | DE60333228D1 (ru) |
ES (1) | ES2347239T3 (ru) |
HK (1) | HK1083023A1 (ru) |
MX (1) | MXPA05005921A (ru) |
RU (1) | RU2377253C2 (ru) |
WO (1) | WO2004050683A2 (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2556815C2 (ru) * | 2010-09-30 | 2015-07-20 | Чэнду Канхун Байотекнолоджис Ко., Лтд. | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ФНО-α, ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab) И ИХ ПРИМЕНЕНИЕ |
US11702479B2 (en) | 2012-08-13 | 2023-07-18 | Genentech, Inc. | Anti-jagged antibodies and methods of use |
Families Citing this family (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
WO2003062278A1 (en) | 2002-01-25 | 2003-07-31 | G2 Therapies Ltd | MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
EP1578799B8 (en) * | 2002-12-02 | 2011-03-23 | Amgen Fremont Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
MXPA05014152A (es) | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
JPWO2005007800A1 (ja) * | 2003-07-18 | 2007-04-12 | 持田製薬株式会社 | 抗血小板膜糖蛋白質viモノクローナル抗体 |
FR2859725B1 (fr) * | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
EP1697417A2 (en) * | 2003-11-07 | 2006-09-06 | Curagen Corporation | Antibodies against secretory leukocyte protease inhibitor |
NZ577824A (en) * | 2003-11-12 | 2010-10-29 | Patrys Ltd | Methods of identifying neoplasm-specific antibodies and uses thereof |
MXPA06008839A (es) * | 2004-02-06 | 2008-03-07 | Univ Massachusetts | Anticuerpos contra toxinas de clostridium difficile y usos de los mismos. |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20060099203A1 (en) | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
PL1768999T3 (pl) * | 2004-06-30 | 2013-12-31 | Mayo Found Medical Education & Res | Przeciwciało sHIgM12 użyteczne w leczeniu stwardnienia rozsianego |
US7501119B2 (en) | 2004-06-30 | 2009-03-10 | Mayo Foundation For Medical Education And Research | Methods and molecules for modulating an immune response |
GB0425972D0 (en) * | 2004-11-25 | 2004-12-29 | Celltech R&D Ltd | Biological products |
WO2006063150A2 (en) * | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
PT1846451E (pt) * | 2005-01-24 | 2013-08-28 | Elan Pharma Int Ltd | Membros de ligação específica para ngf |
TW200724548A (en) * | 2005-04-25 | 2007-07-01 | Pfizer | Antibodies to myostatin |
PE20080035A1 (es) * | 2005-09-07 | 2008-01-30 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
CN1954882A (zh) * | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
RS20080200A (en) | 2005-11-14 | 2009-07-15 | Rinat Neuroscience Corp., | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
WO2007076524A2 (en) | 2005-12-29 | 2007-07-05 | Centocor, Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
US9101760B2 (en) | 2009-11-13 | 2015-08-11 | U3 Pharma Gmbh | Material and methods for treating or preventing HER-3 associated diseases |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
AU2006332713B2 (en) | 2005-12-30 | 2013-01-17 | Takeda Pharmaceutical Company Limited | Metalloproteinase binding proteins |
WO2007100937A2 (en) * | 2006-01-19 | 2007-09-07 | The Regents Of The University Of Michigan | System and method for spectroscopic photoacoustic tomography |
CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
US20080123083A1 (en) * | 2006-11-29 | 2008-05-29 | The Regents Of The University Of Michigan | System and Method for Photoacoustic Guided Diffuse Optical Imaging |
KR20170037677A (ko) * | 2007-01-30 | 2017-04-04 | 에피백스, 인크. | 조절 t 세포 에피토프, 그의 조성물 및 용도 |
US7807168B2 (en) * | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
BRPI0811782A2 (pt) | 2007-05-21 | 2019-02-26 | Alder Biopharmaceuticals, Inc. | anticorpos para il-6 e uso dos mesmos |
WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
WO2008141511A1 (fr) * | 2007-05-22 | 2008-11-27 | Human Antibodomics (Shanghai) Inc. | ANTICORPS MONOCLONAL HUMAIN ANTI-TNFα ET SON UTILISATION |
US20110268749A1 (en) * | 2007-07-31 | 2011-11-03 | The Government of the US as Represented by the Secretary Department of Health and Human Services | Treatment of cancer via targeting of il-13 receptor-alpha2 |
EP2231186A4 (en) | 2007-12-17 | 2012-08-08 | Dyax Corp | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS |
CA2714296A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
EP3441087A1 (en) | 2008-03-04 | 2019-02-13 | Teva Pharmaceuticals International GmbH | Methods of treating chronic pain |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
NZ589436A (en) | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2009149189A2 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
JP5674654B2 (ja) | 2008-07-08 | 2015-02-25 | アッヴィ・インコーポレイテッド | プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用 |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
CN101896502B (zh) * | 2009-03-20 | 2012-10-17 | 刘庆法 | 抗人TNFα单抗、分子进化及其应用 |
CN102762593B (zh) | 2009-07-31 | 2015-05-20 | 梅达雷克斯有限责任公司 | 抗btla的完全人抗体 |
WO2011015919A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant infliximab |
US8623366B2 (en) | 2009-08-28 | 2014-01-07 | Labrys Biologics, Inc. | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011066378A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat thrombosis |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
CN102167741B (zh) * | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗TNF-α单克隆抗体、其制备方法及用途 |
CA2795734A1 (en) * | 2010-04-07 | 2011-10-13 | Abbvie Inc. | Tnf-.alpha. binding proteins |
WO2012018790A2 (en) | 2010-08-03 | 2012-02-09 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
MX2013002270A (es) | 2010-08-26 | 2013-05-14 | Abbvie Inc | Inmonoglubinas de dominio variable doble y usos de las mismas. |
US20120128701A1 (en) | 2010-09-09 | 2012-05-24 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
DK2643018T3 (da) | 2010-11-23 | 2021-01-18 | Vitaeris Inc | Anti-il-6-antistoffer til behandling af oral mucositis |
AR084210A1 (es) * | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
CN103702682A (zh) | 2011-04-21 | 2014-04-02 | 科罗拉多州立大学董事会法人团体 | 治疗视神经脊髓炎的组合物和方法 |
TWI609888B (zh) | 2011-05-20 | 2018-01-01 | 艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽(anti-cgrp)或抗降血鈣素基因相關胜肽受器(anti-cgrp-r)抗體或抗體片段治療或預防慢性及急性型腹瀉之用途 |
EP3508501A1 (en) | 2011-05-20 | 2019-07-10 | AlderBio Holdings LLC | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
PL2710039T3 (pl) | 2011-05-20 | 2019-07-31 | Alderbio Holdings Llc | Kompozycje przeciwko CGRP i ich zastosowanie |
JP6141834B2 (ja) | 2011-06-06 | 2017-06-07 | ノヴォ ノルディスク アー/エス | 治療抗体 |
JP2014523745A (ja) * | 2011-07-20 | 2014-09-18 | メディミューン リミテッド | 抗cxcr4抗体及び使用方法 |
US10314909B2 (en) | 2011-10-21 | 2019-06-11 | Dyax Corp. | Combination therapy comprising an MMP-14 binding protein |
US9803009B2 (en) * | 2011-10-24 | 2017-10-31 | Abbvie Inc. | Immunobinders directed against TNF |
TW201323441A (zh) | 2011-10-24 | 2013-06-16 | Abbvie Inc | 抗tnf之雙特異性免疫結合物 |
TW201323440A (zh) | 2011-10-24 | 2013-06-16 | Abbvie Inc | 抗骨硬化素(sclerostin)之免疫結合物 |
PE20150159A1 (es) | 2011-12-21 | 2015-02-08 | Novartis Ag | Composiciones y metodos para anticuerpos que actuan sobre el factor p |
WO2013102042A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
AR090047A1 (es) * | 2011-12-30 | 2014-10-15 | Abbvie Inc | Dominio variable dual de inmunoglobulinas y sus usos |
WO2013165972A2 (en) * | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
TWI601745B (zh) | 2012-11-01 | 2017-10-11 | 艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
DK3030682T3 (da) | 2013-08-05 | 2020-09-14 | Twist Bioscience Corp | De novo synthesized gene libraries |
CA2923145A1 (en) | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
US20150086561A1 (en) * | 2013-09-26 | 2015-03-26 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
EP3094973B1 (en) | 2013-11-07 | 2020-07-29 | Diagnodus Limited | Biomarkers |
AU2015217278B2 (en) | 2014-02-14 | 2020-03-19 | Macrogenics, Inc. | Improved methods for the treatment of vascularizing cancers |
CN104892760B (zh) * | 2014-03-04 | 2018-04-17 | 北京安保康生物医药科技有限公司 | 抗TNFα的全人源单克隆抗体及其应用 |
HRP20240159T1 (hr) | 2014-03-21 | 2024-04-12 | Teva Pharmaceuticals International Gmbh | Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
MX2016014761A (es) | 2014-05-16 | 2017-05-25 | Amgen Inc | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). |
EP3212231B1 (en) | 2014-10-27 | 2021-04-28 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
AU2015342936B2 (en) | 2014-11-06 | 2020-10-08 | Scholar Rock, Inc. | Anti-pro/latent-Myostatin antibodies and uses thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
JP6917902B2 (ja) | 2015-02-13 | 2021-08-11 | ソレント・セラピューティクス・インコーポレイテッド | Ctla4に結合する抗体医薬 |
US10100118B2 (en) * | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
EP4292664A3 (en) * | 2015-05-15 | 2024-06-12 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
JP2018528763A (ja) | 2015-07-31 | 2018-10-04 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | バイオフィルムの除去のためのペプチドおよび抗体 |
SI3350220T1 (sl) | 2015-09-15 | 2021-12-31 | Scholar Rock, Inc. | Protitelesa proti pro/latentnemu miostatinu in uporabe le-teh |
CA2998169A1 (en) | 2015-09-18 | 2017-03-23 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
WO2017120523A2 (en) | 2016-01-08 | 2017-07-13 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
JP6974348B2 (ja) * | 2016-01-09 | 2021-12-01 | アーベル リミテッドArbele Limited | がん処置のためのカドヘリン−17特異的抗体及び細胞傷害性細胞 |
US10774140B2 (en) | 2016-03-17 | 2020-09-15 | Numab Therapeutics AG | Anti-TNFα-antibodies and functional fragments thereof |
AU2017283546C1 (en) | 2016-06-13 | 2020-11-19 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
US10781260B2 (en) | 2016-08-08 | 2020-09-22 | Sorrento Therapeutics, Inc. | Anti-OX40 binding proteins |
JP6871364B2 (ja) | 2016-09-21 | 2021-05-12 | ツイスト バイオサイエンス コーポレーション | 核酸に基づくデータ保存 |
PE20191148A1 (es) | 2016-09-23 | 2019-09-02 | Teva Pharmaceuticals Int Gmbh | Tratamiento de la migrana refractaria |
EP3558369A4 (en) | 2016-12-21 | 2020-09-09 | Cephalon, Inc. | ANTIBODIES SPECIFICALLY BINDING TO HUMAN IL-15 AND THEIR USES |
AU2018206552A1 (en) | 2017-01-04 | 2019-07-18 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
WO2018129092A1 (en) | 2017-01-04 | 2018-07-12 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
DK3565592T5 (da) | 2017-01-06 | 2024-09-02 | Scholar Rock Inc | Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering |
EP3586255A4 (en) | 2017-02-22 | 2021-03-31 | Twist Bioscience Corporation | NUCLEIC ACID-BASED DATA STORAGE |
AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
JP7169999B2 (ja) | 2017-06-12 | 2022-11-11 | ツイスト バイオサイエンス コーポレーション | シームレス核酸アセンブリのための方法 |
JP7356970B2 (ja) * | 2017-06-25 | 2023-10-05 | システィミューン, インク. | 多重特異性抗体とその作製及び使用方法 |
KR20200047706A (ko) | 2017-09-11 | 2020-05-07 | 트위스트 바이오사이언스 코포레이션 | Gpcr 결합 단백질 및 이의 합성 방법 |
JP7066840B2 (ja) | 2017-10-20 | 2022-05-13 | ツイスト バイオサイエンス コーポレーション | ポリヌクレオチド合成のための加熱されたナノウェル |
US11142579B2 (en) | 2017-12-06 | 2021-10-12 | Sorrento Therapeutics, Inc. | Variant antibodies that bind OX40 |
CA3088911A1 (en) | 2018-01-04 | 2019-07-11 | Twist Bioscience Corporation | Dna-based storage device and method for synthesizing polynucleotides using the device |
KR20200135781A (ko) | 2018-03-26 | 2020-12-03 | 암젠 인크 | 세포 배양에서 생산된 항체의 총 비푸코실화 당형태 |
CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
MX2021001510A (es) * | 2018-08-08 | 2021-07-02 | Dragonfly Therapeutics Inc | Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores. |
EP3883607A4 (en) | 2018-11-20 | 2022-08-17 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY |
JP2022516956A (ja) | 2019-01-08 | 2022-03-03 | ハー・ルンドベック・アクチエゼルスカベット | 抗cgrp抗体を用いた頭痛の急性治療及び迅速治療 |
EP3938506A4 (en) | 2019-02-26 | 2022-12-14 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR OPTIMIZATION OF ANTIBODIES |
AU2020251028A1 (en) * | 2019-04-04 | 2021-10-28 | Janssen Biotech, Inc. | Anti-HLA-C antibodies and uses thereof |
JP2022527372A (ja) * | 2019-04-08 | 2022-06-01 | バイオジェン・エムエイ・インコーポレイテッド | 抗インテグリン抗体及びそれらの使用 |
BR112021023295A2 (pt) | 2019-05-23 | 2022-02-08 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
US11332738B2 (en) | 2019-06-21 | 2022-05-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
US20220259290A1 (en) * | 2019-07-24 | 2022-08-18 | Japan Science And Technology Agency | Innovative production technique for antibody-enzyme |
EP4034566A4 (en) | 2019-09-23 | 2024-01-24 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR CRTH2 |
KR20220069982A (ko) | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
CN111153994B (zh) * | 2019-12-31 | 2021-10-15 | 武汉班科生物技术股份有限公司 | 人肿瘤坏死因子的人源单克隆抗体 |
WO2021154530A1 (en) * | 2020-01-27 | 2021-08-05 | Vanderbilt University | Human anti-dengue antibodies and methods of use therefor |
WO2021222128A1 (en) * | 2020-04-27 | 2021-11-04 | Fred Hutchinson Cancer Research Center | Neutralizing monoclonal antibodies against covid-19 |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
WO2022019671A1 (ko) * | 2020-07-23 | 2022-01-27 | (주)셀트리온 | 사스-코로나바이러스-2 스파이크 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자 |
KR20230074151A (ko) * | 2020-08-26 | 2023-05-26 | 트위스트 바이오사이언스 코포레이션 | Glp1r 변이체에 관한 방법 및 조성물 |
AU2021360897A1 (en) | 2020-10-15 | 2023-05-25 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
EP4261222A1 (en) | 2020-12-09 | 2023-10-18 | HK inno.N Corporation | ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFalpha BISPECIFIC ANTIBODY, AND USES THEREOF |
CA3222409A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
EP4413377A1 (en) | 2021-10-05 | 2024-08-14 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
CN114702578B (zh) * | 2022-06-06 | 2022-09-27 | 百斯医学诊断科技(北京)有限公司 | 新型冠状病毒Omicron突变株特异性抗体及其应用 |
WO2024102700A2 (en) * | 2022-11-09 | 2024-05-16 | IgGenix, Inc. | Compositions and methods for treating and suppressing allergic responses |
CN116789813B (zh) * | 2023-06-27 | 2024-04-26 | 重庆原伦生物科技有限公司 | 一种抗金黄色葡萄球菌α-溶血素的单克隆抗体及其应用 |
Family Cites Families (239)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4309418A (en) * | 1980-03-25 | 1982-01-05 | Sloan-Kettering Research Institute For Cancer | Anti-tumor agent from human serum and process |
EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
SE8204382L (sv) * | 1981-07-21 | 1983-01-22 | Hayashibara Biochem Lab | Sett att framstella malcellysfaktor och anvendning derav |
US6309640B1 (en) | 1981-09-08 | 2001-10-30 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US4822776A (en) * | 1981-09-08 | 1989-04-18 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US5700466A (en) | 1981-09-08 | 1997-12-23 | The Rockefeller University | Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor |
US6419927B1 (en) | 1981-09-08 | 2002-07-16 | Anthony Cerami | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages |
US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
HU189251B (en) * | 1982-04-07 | 1986-06-30 | Asahi Kasei Kogyo Kk,Jp | Process for stabilizing tumor necrosis factor |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4390468A (en) * | 1982-08-04 | 1983-06-28 | Maruzen Oil Co., Ltd. | Preparation of antitumor agent from shellfish |
US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS6019719A (ja) * | 1983-07-15 | 1985-01-31 | Asahi Chem Ind Co Ltd | 抗腫瘍活性を有する蛋白質 |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4678773A (en) * | 1983-08-26 | 1987-07-07 | Chugai Seiyaku Kabushiki Kaisha | Antitumor agent |
EP0142641B1 (de) | 1983-09-26 | 1991-01-16 | Udo Dr. Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
JPS60112718A (ja) | 1983-11-21 | 1985-06-19 | Kyorin Pharmaceut Co Ltd | 抗腫瘍作用を示す蛋白性物質及びその製造方法 |
JPH0695939B2 (ja) | 1983-12-02 | 1994-11-30 | 大日本製薬株式会社 | ウサギ癌壊死因子をコ−ドするクロ−ン化dνa |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5288852A (en) * | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
US4894334A (en) * | 1984-03-28 | 1990-01-16 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
US4656132A (en) * | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
DE3423234A1 (de) | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
WO1986002068A1 (en) | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
US4677064A (en) * | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4677063A (en) * | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
JPS61124392A (ja) | 1984-11-22 | 1986-06-12 | Asahi Chem Ind Co Ltd | 遺伝子組換体の産生する生理活性物質の精製法 |
IL73883A (en) | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
ATE73856T1 (de) * | 1984-12-21 | 1992-04-15 | Biogen Inc | Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren. |
US4900724A (en) * | 1985-03-04 | 1990-02-13 | Sawai Pharmaceutical Co., Ltd | Tumor necrosis factor inducing substance derived from acid-fast bacteria |
US4684623A (en) | 1985-05-02 | 1987-08-04 | The Board Of Trustees Of The Cetus Corporation | Use of tumor necrosis factor as a weight regulator |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
DE3526096A1 (de) * | 1985-07-22 | 1987-01-22 | Basf Ag | Verfahren zur reinigung von htnf |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
US4770995A (en) | 1985-08-29 | 1988-09-13 | New York Blood Center, Inc | Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin |
JPH0698004B2 (ja) | 1985-09-30 | 1994-12-07 | サントリー株式会社 | Tnf発現用新規プラスミド |
US5059530A (en) | 1985-09-30 | 1991-10-22 | Suntory Ltd. | Expression vector for human TNF |
US5182196A (en) * | 1985-10-09 | 1993-01-26 | Biogen, Inc. | Expression systems for overproduction of desired proteins |
US4894439A (en) * | 1986-05-22 | 1990-01-16 | Cetus Corporation | N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes |
US4677197A (en) * | 1985-10-30 | 1987-06-30 | Cetus Corporation | Purification method for tumor necrosis factor |
JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
EP0247906B1 (en) * | 1986-02-04 | 1994-12-28 | Mizuno, Den'Ichi | DNA coding for anti-tumour polypeptides, the polypeptides and anti-tumour agents comprising said polypeptides |
US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
US4863727A (en) | 1986-04-09 | 1989-09-05 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
US5425940A (en) | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
ATE107362T1 (de) * | 1986-06-20 | 1994-07-15 | Dainippon Pharmaceutical Co | Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns. |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5866136A (en) * | 1986-08-01 | 1999-02-02 | Commonwealth Scientific And Industrial Organisation | Recombinant vaccine |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5002876A (en) * | 1986-09-22 | 1991-03-26 | Phillips Petroleum Company | Yeast production of human tumor necrosis factor |
US4777242A (en) | 1986-10-10 | 1988-10-11 | Phillips Petroleum Company | Purification of recombinant tumor necrosis factor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
JPH07106158B2 (ja) | 1986-12-04 | 1995-11-15 | サントリー株式会社 | 抗腫瘍活性を有する新規ポリペプチドおよびその製造法 |
US5504005A (en) * | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
US4894225A (en) * | 1987-03-02 | 1990-01-16 | Cetus Corporation | Combination therapy using antitumor immunotoxins with tumor necrosis factor |
CA1340953C (en) | 1987-04-08 | 2000-04-11 | David W. Barnes | Non-tumorigenic cell lines for expression of genes |
US5075236A (en) | 1987-04-24 | 1991-12-24 | Teijin Limited | Method of detecting kawasaki disease using anti-tumor necrosis antibody |
DE3716513A1 (de) * | 1987-05-16 | 1988-11-24 | Basf Ag | Proteine mit tnf-wirkung |
US6410033B1 (en) * | 1987-07-27 | 2002-06-25 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus |
IL87737A (en) * | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
US5158871A (en) | 1988-02-12 | 1992-10-27 | University Of Connecticut | Method of using magnetic particles for isolating, collecting and assaying diagnostic ligates |
US5183657A (en) * | 1988-03-11 | 1993-02-02 | Celltech Limited | Antibodies for use in antilymphocyte antibody therapy |
US5215743A (en) * | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
US5424940A (en) * | 1988-04-25 | 1995-06-13 | Ousborne; Jeffrey J. | Computer controlled system providing functions within a laundromat facility |
JPH0797997B2 (ja) | 1988-04-28 | 1995-10-25 | 帝人株式会社 | 新規生理活性ポリペプチド |
DE3823804A1 (de) | 1988-07-14 | 1990-01-18 | Basf Ag | Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten |
WO1990000902A1 (en) | 1988-07-18 | 1990-02-08 | Chiron Corporation | Monoclonal antibodies reactive with cachectin |
EP0437610B1 (en) | 1988-09-22 | 1996-06-12 | Teijin Limited | Novel physiologically active polypeptide, recombinant plasmid, recombinant microbial cells, medicinal composition, and process for recovering purified polypeptide |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5360716A (en) | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
DK0393438T3 (da) | 1989-04-21 | 2005-05-30 | Amgen Inc | TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor |
US6232446B1 (en) * | 1989-05-18 | 2001-05-15 | Yeda Research And Development Co. Ltd. | TNF ligands |
US6262239B1 (en) | 1989-05-18 | 2001-07-17 | Yeda Research And Development Co., Ltd. | TNF receptor-specific antibodies |
US5644034A (en) | 1989-08-07 | 1997-07-01 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
US6451983B2 (en) | 1989-08-07 | 2002-09-17 | Peptech Limited | Tumor necrosis factor antibodies |
DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
US6315999B1 (en) | 1989-08-10 | 2001-11-13 | Solvay, S.A. | Pharmaceutical product for the treatment of sepsis |
JPH05501351A (ja) | 1989-08-16 | 1993-03-18 | カイロン コーポレイション | プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用 |
US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
AU661652B2 (en) * | 1989-10-24 | 1995-08-03 | Chiron Corporation | Infective protein delivery system |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5672510A (en) | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5110913A (en) * | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
WO1992002551A1 (en) * | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
WO1992003145A1 (en) | 1990-08-27 | 1992-03-05 | Peptide Technology Ltd. | Method of treating viral infection |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5612205A (en) | 1990-08-29 | 1997-03-18 | Genpharm International, Incorporated | Homologous recombination in mammalian cells |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
US5519119A (en) * | 1990-09-21 | 1996-05-21 | Ishihara Sangyo Kaisha Ltd. | Muteins of TNF pharmaceutical compositions and a method of making |
JPH05255393A (ja) | 1990-09-21 | 1993-10-05 | Ishihara Sangyo Kaisha Ltd | ポリペプチド |
US5653974A (en) | 1990-10-18 | 1997-08-05 | Board Of Regents,The University Of Texas System | Preparation and characterization of liposomal formulations of tumor necrosis factor |
GB9022648D0 (en) * | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
CA2055168A1 (en) * | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
ATE164395T1 (de) * | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5994510A (en) | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
CA2106299C (en) | 1991-03-18 | 2001-02-06 | Junming Le | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
US5160483A (en) | 1991-05-07 | 1992-11-03 | The University Of Tennessee Research Corporation | Fragment of TNF-α for promoting wound healing |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
FR2677654B1 (fr) | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
US5633146A (en) | 1991-07-02 | 1997-05-27 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant proteins and host cells used therein |
US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
US5965379A (en) | 1991-07-19 | 1999-10-12 | Cytimmune Sciences Inc. | Method for measuring endogenous cytokines |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
FR2679920A1 (fr) * | 1991-08-02 | 1993-02-05 | Rhone Poulenc Rorer Sa | Levures recombinantes hautement stables pour la production de proteines recombinantes, leur preparation et leur utilisation. |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5334380A (en) | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6261834B1 (en) | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
PT1024191E (pt) * | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CZ283533B6 (cs) * | 1992-04-02 | 1998-04-15 | F. Hoffmann-La Roche Ag | TNF - muteiny a způsob jejich výroby |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
US5278284A (en) * | 1992-05-14 | 1994-01-11 | Miller Brewing Company | Protein purification method |
WO1994000569A1 (en) | 1992-06-18 | 1994-01-06 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
EP0585705B1 (en) * | 1992-08-28 | 1998-11-04 | Bayer Corporation | Use of monoclonal antibodies to TNF to treat bacterial meningitis |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
WO1994008619A1 (en) * | 1992-10-08 | 1994-04-28 | The Kennedy Institute Of Rheumatology | Treatment of autoimmune and inflammatory disorders |
AU682156B2 (en) * | 1992-10-15 | 1997-09-25 | Dana-Farber Cancer Institute, Inc. | Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function |
US5968735A (en) | 1992-11-12 | 1999-10-19 | Max Delbruck-Centrum Fur Molekular Medizin Berlin | Vector for the expression of therapy-relevant genes |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
WO1994018325A1 (en) * | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Tnf-alpha muteins and a process for preparing them |
KR970005042B1 (ko) * | 1993-02-09 | 1997-04-11 | 한일합성섬유공업 주식회사 | 종양괴사인자-알파 뮤테인 |
US5626843A (en) * | 1993-02-26 | 1997-05-06 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor |
EP0614984B2 (en) * | 1993-03-05 | 2010-11-03 | Bayer HealthCare LLC | Anti-TNF alpha human monoclonal antibodies |
CA2119089A1 (en) * | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
AU678483B2 (en) * | 1993-06-03 | 1997-05-29 | Protherics Inc. | Antibody fragments in therapy |
ATE196849T1 (de) | 1993-07-30 | 2000-10-15 | Kennedy Inst Of Rheumatology | Verfahren zur behandlung von multiplesklerose |
FR2709309B1 (fr) * | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Compositions cellulaires, préparation et utilisations thérapeutiques. |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5959085A (en) | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
ES2316148T3 (es) * | 1994-03-23 | 2009-04-01 | Ohio University | Acidos nucleicos compactados y su suministro a celulas. |
DE69523586T2 (de) * | 1994-05-17 | 2002-07-18 | Cedars-Sinai Medical Center, Los Angeles | Verfahren zum screening für die erkrankung crohn durch die verwendung von tnf-mikrosatelliten allelen |
US5606023A (en) * | 1994-05-24 | 1997-02-25 | Thomas Jefferson University | Mutant tumor necrosis factor proteins |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
US5989808A (en) | 1994-06-14 | 1999-11-23 | American Cyanamid Company | Identification of compounds affecting specific interaction of peptide binding pairs |
DE4435612A1 (de) | 1994-10-05 | 1996-04-11 | Braun Melsungen Ag | Verfahren zur simultanen Entfernung von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus einer wäßrigen Flüssigkeit |
US5763733A (en) * | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US5753499A (en) * | 1994-12-23 | 1998-05-19 | New York University | Viral vector complexes having adapters of predefined valence |
US6127528A (en) | 1995-02-16 | 2000-10-03 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for adsorbing and removing tumor necrosis factor-α |
ATE201983T1 (de) * | 1995-03-10 | 2001-06-15 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
WO1997007671A1 (fr) | 1995-08-29 | 1997-03-06 | Kirin Beer Kabushiki Kaisha | Animal chimerique et procede de constitution |
US6022737A (en) * | 1995-11-02 | 2000-02-08 | Amgen Inc. | Formulations for non-viral in vivo transfection in the lungs |
FR2741262B1 (fr) * | 1995-11-20 | 1999-03-05 | Oreal | Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5789442A (en) * | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
PL188192B1 (pl) * | 1996-02-09 | 2004-12-31 | Abbott Lab Bermuda Ltd | Izolowane ludzkie przeciwciało albo jego część wiążąca antygen, rekombinowane ludzkie przeciwciało albo jego część wiążąca antygen, kompozycje farmaceutyczne, izolowane kwasy nukleinowe, rekombinowany wektor ekspresyjny, komórka gospodarza, sposób syntetyzowania przeciwciała ludzkiego, które wiąże ludzki TNFalfa, sposób hamowania aktywności ludzkiego TNFalfa in vitro, przeciwciało albo jego częśćwiążąca antygen, zastosowanie przeciwciała albo jego części wiążącej antygen |
DE69700344T2 (de) * | 1996-02-23 | 2000-01-27 | Samsung Electronics Co Ltd | Verfahren zum Steuern eines Mikrowellenofens zum Vermeiden des Übergarens kleiner Speiseportionen |
EP0791360A3 (en) | 1996-02-29 | 1997-09-24 | Bayer Corporation | Treatment of septic shock with anti-TNF antibodies |
US5952221A (en) * | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
JP4124486B2 (ja) * | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
US6080382A (en) * | 1996-12-31 | 2000-06-27 | Chevron U. S. A. Inc. | Zeolite SSZ-48 |
US5917123A (en) * | 1997-03-14 | 1999-06-29 | University Of Pittsburgh | Transgenic mice containing a nucleic acid encoding tumor necrosis factor-α under the control of a cardiac specific regulatory region |
US6099847A (en) | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
CA2293718A1 (en) * | 1997-06-10 | 1998-12-17 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
GB9713412D0 (en) * | 1997-06-26 | 1997-08-27 | Delta Biotechnology Ltd | Improved protein expression strains |
US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
WO1999037755A2 (en) * | 1997-12-11 | 1999-07-29 | Pangene Corporation | The use of consensus sequences for targeted homologous gene isolation and recombination in gene families |
EP1049773B1 (en) | 1998-01-22 | 2007-07-25 | Btg International Limited | Inhibition of cytokine production |
IL140785A0 (en) * | 1998-07-13 | 2002-02-10 | Expression Genetics Inc | Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
US6015557A (en) * | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
PT1187611E (pt) * | 1999-06-03 | 2004-10-29 | Maxim Pharm Inc | Composicoes oftalmicas de histamina e sua utilizacoes |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
ATE461692T1 (de) * | 1999-10-29 | 2010-04-15 | Novartis Ag | Trockenpulverzusammensetzungen mit verbesserter dispersität |
US6524572B1 (en) * | 2000-06-26 | 2003-02-25 | Rainbow Therapeutic Company | Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy |
DE60222816T2 (de) | 2001-12-03 | 2008-07-03 | Amgen Fremont Inc. | Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung |
EP1578799B8 (en) * | 2002-12-02 | 2011-03-23 | Amgen Fremont Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2003
- 2003-12-02 EP EP03796574A patent/EP1578799B8/en not_active Expired - Lifetime
- 2003-12-02 US US10/727,155 patent/US7285269B2/en not_active Expired - Lifetime
- 2003-12-02 AU AU2003298816A patent/AU2003298816C1/en not_active Expired
- 2003-12-02 WO PCT/US2003/038281 patent/WO2004050683A2/en active Application Filing
- 2003-12-02 RU RU2005116225/13A patent/RU2377253C2/ru active
- 2003-12-02 JP JP2004557489A patent/JP4754219B2/ja not_active Expired - Lifetime
- 2003-12-02 DE DE60333228T patent/DE60333228D1/de not_active Expired - Lifetime
- 2003-12-02 AT AT03796574T patent/ATE472556T1/de not_active IP Right Cessation
- 2003-12-02 CN CNB2003801094561A patent/CN100434440C/zh not_active Expired - Lifetime
- 2003-12-02 MX MXPA05005921A patent/MXPA05005921A/es active IP Right Grant
- 2003-12-02 CA CA2508375A patent/CA2508375C/en not_active Expired - Lifetime
- 2003-12-02 ES ES03796574T patent/ES2347239T3/es not_active Expired - Lifetime
-
2006
- 2006-03-09 HK HK06103052.3A patent/HK1083023A1/xx not_active IP Right Cessation
-
2007
- 2007-10-22 US US11/876,669 patent/US8101178B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2556815C2 (ru) * | 2010-09-30 | 2015-07-20 | Чэнду Канхун Байотекнолоджис Ко., Лтд. | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ФНО-α, ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab) И ИХ ПРИМЕНЕНИЕ |
US11702479B2 (en) | 2012-08-13 | 2023-07-18 | Genentech, Inc. | Anti-jagged antibodies and methods of use |
Also Published As
Publication number | Publication date |
---|---|
US20050049402A1 (en) | 2005-03-03 |
WO2004050683A8 (en) | 2005-07-28 |
RU2005116225A (ru) | 2006-02-27 |
US8101178B2 (en) | 2012-01-24 |
ATE472556T1 (de) | 2010-07-15 |
AU2003298816B2 (en) | 2010-06-17 |
MXPA05005921A (es) | 2005-10-19 |
US20080187531A1 (en) | 2008-08-07 |
JP4754219B2 (ja) | 2011-08-24 |
AU2003298816C1 (en) | 2010-12-16 |
US7285269B2 (en) | 2007-10-23 |
JP2006508167A (ja) | 2006-03-09 |
WO2004050683A2 (en) | 2004-06-17 |
AU2003298816A1 (en) | 2004-06-23 |
CA2508375A1 (en) | 2004-06-17 |
HK1083023A1 (en) | 2006-06-23 |
EP1578799A4 (en) | 2007-04-04 |
DE60333228D1 (de) | 2010-08-12 |
CN100434440C (zh) | 2008-11-19 |
EP1578799B8 (en) | 2011-03-23 |
CN1745101A (zh) | 2006-03-08 |
WO2004050683A3 (en) | 2005-04-14 |
ES2347239T3 (es) | 2010-10-27 |
EP1578799B1 (en) | 2010-06-30 |
CA2508375C (en) | 2014-05-27 |
EP1578799A2 (en) | 2005-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2377253C2 (ru) | Антитела, специфичные к фактору некроза опухолей, и их применение | |
RU2486204C2 (ru) | Антитела против сd26 и способы их применения | |
RU2395523C2 (ru) | Антитела к ох40l | |
RU2457219C2 (ru) | Антигенсвязывающие молекулы, которые связывают рецептор эпидермального фактора роста (egfr), кодирующие их векторы и их применение | |
JP4294596B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
CN102782148A (zh) | 与多种cc趋化因子结合的抗因子抗体 | |
CN101851291B (zh) | 一种抗人baff单克隆抗体的重链和轻链可变区 | |
CN103261222A (zh) | 抗体衍生物 | |
ATE435239T1 (de) | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen | |
JP6010127B2 (ja) | 改変抗体およびその作製方法 | |
CN101440130B (zh) | 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区 | |
MY145703A (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors | |
RU2003126168A (ru) | Терапевтические связывающие молекулы | |
RU2550262C1 (ru) | Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело | |
CN103265631B (zh) | 一种抗人crt单克隆抗体的重链和轻链可变区 | |
US9062120B2 (en) | Binding proteins having tethered light chains | |
CN101585880B (zh) | 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区 | |
CN111909268B (zh) | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 | |
CN1986794A (zh) | 抗炭疽芽孢杆菌保护性抗原单克隆抗体轻、重链可变区基因及其应用 | |
CN1294263C (zh) | 人b淋巴细胞刺激因子单克隆抗体的重链和轻链可变区基因及其应用 | |
CN1255536C (zh) | 高亲和力抗肿瘤坏死因子单克隆抗体的可变区基因及其制备 | |
Xia | Structure, Classification, and Naming of Therapeutic Monoclonal Antibodies | |
CN1255537C (zh) | 高中和活性抗肿瘤坏死因子单克隆抗体的可变区基因及其制备 | |
CN100436580C (zh) | 高中和活性抗肿瘤坏死因子单克隆抗体的可变区基因及其制备 | |
RU2024100707A (ru) | Биспецифические антитела к ccl2 |